Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in the salvage setting have been limited to conventional cytotoxic chemotherapy with minimal activity. Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
acute lymphoblastic
8
lymphoblastic leukemia
8
treatment relapsed/refractory
4
relapsed/refractory acute
4
leukemia patients
4
patients relapsed
4
relapsed refractory
4
refractory acute
4
leukemia r/r
4
r/r dismal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!